治疗乳腺癌新药——周期蛋白依赖性激酶4/6抑制剂abemaciclib

A new drug in treatment of breast cancer——CDK4/6 inhibitor abemaciclib

abemaciclib是礼来公司研发的周期蛋白依赖性激酶4/6抑制剂,单独用药对转移性乳腺癌有显著疗效。2015年10月被美国食品和药物管理局(FDA)视为治疗乳腺癌的突破性药物,2017年9月被FDA批准上市。本文主要介绍其药物作用机制、药效学、药动学、临床试验和安全性等。

Abemaciclib is a cyclin-dependent kinase（CDK） 4/6 inhibitor developed by Eli Lilly and Company, and its single drug use has a significant effect on metastatic breast cancer. Abemaciclib has been considered as a breakthrough drug for the treatment of breast cancer by U.S. Food and Drug Administration on October, 2015 and was approved on September, 2017. This article reviewed the mechanism of drug action,pharmacodynamics, pharmacokinetics, clinical trials, and safety.